These findings indicate that the specificity of this class of inhibitors against the EGFR T790M oncoprotein may provide the ability to achieve clinical concentrations sufficient to effectively target tumor cells that express EGFR T790M and spare cells that express WT EGFR. The gene discussed is EGFR; the disease is neoplasm.